23andMe's MAP Report Receives FDA's 510(k) Clearance for Hereditary Colorectal Cancers
Shots:
- MAP Report is a direct-to-consumer genetic test and has received FDA approval for MUTYH-associated polyposis (MAP)- a hereditary colorectal cancer syndrome
- Post-FDA approval for BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report in Mar 2018- 23andMe has received its second FDA approval for MAP Report detecting two variants in people with MAP
- The approval allows patients for genetic testing with accurate results & is available for patients with educational module choosing to view their MAP report
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
